Excluding its coronavirus antibody drug, Regeneron has long counted Eylea as its top-selling product. Last year, net sales of the eye therapy totaled $5.8 billion in the U.S. and $3.6 billion across the rest of the world, where Regeneron’s partner Bayer is in charge of commercialization.
First approved in 2011 for a certain kind of AMD, Eylea’s market dominance has persisted for roughly a decade, outselling rival treatments like Roche’s Lucentis. But challenges are mounting. The Food and Drug Administration last fall approved Susvimo, a refillable implant that continuously administers a formulation of Lucentis and that could be seen, at least by some patients, as a more convenient option than Eylea, which is administered every month or two as an injection into the eye.
